PTPRJ Antibody

Basic Research Questions

• What is PTPRJ and why are antibodies against it important for research?

  PTPRJ (CD148) is a membrane-associated receptor-type protein tyrosine phosphatase belonging to the Receptor class 3 subfamily. The 220 kDa glycoprotein consists of an extracellular domain with eight fibronectin III motifs, a transmembrane domain, and an intracellular catalytic domain .

  PTPRJ antibodies are crucial research tools because they enable:

  • Detection and quantification of PTPRJ expression in different tissues

  • Visualization of subcellular localization

  • Immunoprecipitation for studying protein-protein interactions

  • Flow cytometric analysis of cell surface expression

  • Investigation of PTPRJ's roles in various signaling pathways

• What applications are PTPRJ antibodies commonly used for?

  PTPRJ antibodies are utilized in multiple experimental techniques:

  Application	Common Dilutions	Notes
  Western Blot	1:500-1:1000	Detects 146-170 kDa band
  Immunohistochemistry	1:100-1:400	Requires antigen retrieval
  Flow Cytometry	Application-specific	Used with fluorochrome-conjugated antibodies
  ELISA	Application-specific	For quantitative protein detection
  Immunoprecipitation	4-8 μg antibody per 600-1000 μg lysate	Used for protein complex isolation

  Methodological consideration: Always validate the antibody for your specific application and cell/tissue type, as performance can vary between experimental systems.

• How should researchers select the appropriate PTPRJ antibody for their experiments?

  Selection criteria should include:

  • Target epitope: Different antibodies recognize distinct regions of PTPRJ (e.g., extracellular domain AA 1-444 , AA 36-210 , or intracellular regions)

  • Host species: Consider compatibility with other antibodies in multi-color or co-staining experiments

  • Clonality: Monoclonal for specific epitopes; polyclonal for broader detection

  • Application validation: Verify the antibody has been tested for your specific application

  • Conjugation: Choose unconjugated for flexibility or directly conjugated (PE, APC, FITC) for flow cytometry

  • Cross-reactivity: Check species reactivity matches your experimental model

  Methodological approach: For critical experiments, test multiple antibodies targeting different epitopes to confirm findings and rule out antibody-specific artifacts.

• How can researchers validate the specificity of PTPRJ antibodies?

  A comprehensive validation approach includes:

  • Positive controls: Use cell lines with known PTPRJ expression (e.g., HepG2, HeLa, Jurkat, K-562, PC-3)

  • Negative controls: Use PTPRJ knockout cells (e.g., PTPRJ KO cell lines as demonstrated in FLT3 studies)

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

  • siRNA knockdown: Compare detection in cells with and without PTPRJ knockdown

  • Multiple antibodies: Use antibodies targeting different epitopes to confirm results

  • Expected molecular weight: Verify detection at 146-170 kDa (PTPRJ is heavily glycosylated)

  Important note: Expression levels and molecular weight can vary by cell type due to post-translational modifications, particularly glycosylation.

• What are the recommended protocols for using PTPRJ antibodies in immunohistochemistry?

  For optimal IHC results:

  1. Tissue preparation: Use formalin-fixed, paraffin-embedded sections (4-6 μm thickness)

  2. Antigen retrieval: Use TE buffer pH 9.0 (primary recommendation) or citrate buffer pH 6.0 as an alternative

  3. Blocking: Block with appropriate serum (5-10%) based on secondary antibody host

  4. Primary antibody: Apply at 1:100-1:400 dilution ; incubate overnight at 4°C

  5. Detection system: Use appropriate secondary antibody and visualization system

  6. Controls: Include positive control tissue (e.g., human tonsillitis tissue)

  Methodological consideration: Titrate antibody concentration to determine optimal signal-to-noise ratio for each tissue type. Different fixation methods may require protocol adjustments.

Advanced Research Questions

• How can PTPRJ antibodies be used to investigate its role in tumor suppression?

  Multi-faceted approaches include:

  1. Comparative expression analysis: Use antibodies to quantify PTPRJ levels across normal vs. tumor tissues via:

     • IHC analysis of tumor microarrays

     • Western blot quantification from patient samples

     • Flow cytometry for cell surface expression in primary cells

  2. Mechanistic studies:

     • Immunoprecipitate PTPRJ to identify interacting partners in tumor vs. normal cells

     • Use proximity ligation assays to visualize PTPRJ interactions with RTKs in situ

     • Combine with phospho-specific antibodies to correlate PTPRJ expression with downstream signaling

  3. Functional validation:

     • After manipulating PTPRJ expression, use antibodies to confirm levels in gain/loss-of-function experiments

     • Track cellular localization changes during tumor progression

  Research example: PTPRJ has been associated with several tumors, including colorectal, breast, and lung neoplasms . Researchers can investigate these connections using appropriate antibodies for tissue-specific expression analysis.

• What methodologies can be used to study PTPRJ homodimerization and its impact on phosphatase activity?

  Several complementary techniques can be employed:

  1. Co-immunoprecipitation: Use HA-tagged PTPRJ constructs and anti-HA antibodies to isolate protein complexes and analyze oligomerization states as demonstrated in transmembrane domain mutant studies

  2. Crosslinking studies: Apply membrane-permeable crosslinkers followed by antibody detection to capture transient interactions

  3. FRET/BRET analysis: Utilize tagged constructs to monitor protein-protein interactions in living cells

  4. Phosphatase activity assays: Following immunoprecipitation with PTPRJ antibodies, measure enzymatic activity using:

     • pNPP hydrolysis assays

     • Phosphopeptide dephosphorylation assays

     • In-gel phosphatase assays

  Research insight: Studies have shown that disrupting PTPRJ transmembrane-mediated oligomerization through specific Glycine-to-Leucine mutations (G979L, G983L, G987L) increases its phosphatase activity in situ and impairs oncogenic FLT3 signaling .

• How can researchers use PTPRJ antibodies to study its role in regulating receptor tyrosine kinases in leukemia?

  Methodological approaches include:

  1. Co-immunoprecipitation studies:

     • Immunoprecipitate PTPRJ using specific antibodies

     • Probe for associated RTKs (e.g., FLT3, EGFR) in the complex

     • Perform reverse IP with RTK antibodies and probe for PTPRJ

  2. Phosphorylation analysis:

     • After manipulating PTPRJ expression, use phospho-specific antibodies to assess RTK phosphorylation status

     • Example: In cells expressing PTPRJ TMD mutants, researchers observed reduced FLT3 ITD autophosphorylation and diminished downstream signaling through pSTAT5, pAKT, and pERK1/2

  3. Cell-based functional assays:

     • Following confirmation of PTPRJ manipulation using antibodies, assess:

       • Proliferation rates

       • Colony formation in soft agar

       • Cell cycle progression

       • Apoptosis markers

  Experimental design: The study by Shlyakhtina et al. demonstrated how PTPRJ TMD mutant proteins impaired FLT3 activity and FLT3-driven cell phenotypes in AML cells, suggesting a potential therapeutic strategy.

• What techniques can be employed to detect and study the soluble form of PTPRJ (sPTPRJ)?

  The soluble PTPRJ isoform (sPTPRJ) requires specialized detection approaches:

  1. Western blot analysis:

     • Collect conditioned media from cells

     • Concentrate proteins using filters (e.g., Amicon Ultra-15 Centrifugal Filter Units)

     • Use antibodies targeting the extracellular domain of PTPRJ

  2. Immunoprecipitation from media:

     • Use antibodies against sPTPRJ to pull down the secreted protein

     • Verify glycosylation status through glycosidase treatment followed by Western blot

  3. ELISA development:

     • Design sandwich ELISA using two antibodies recognizing different epitopes

     • Quantify sPTPRJ in biological fluids or culture supernatants

  4. Functional studies:

     • After confirming sPTPRJ presence, assess its effects on:

       • Endothelial cell tube formation

       • Wound healing assays

       • Regulation of endothelial adhesion molecules

  Research finding: Studies have shown that sPTPRJ has proangiogenic activity and that sPTPRJ mRNA levels are higher in human high-grade glioma samples compared to controls .

• How can flow cytometry with PTPRJ antibodies be optimized for studying primary cells and cell lines?

  For optimal flow cytometry results:

  1. Antibody selection:

     • Choose directly conjugated antibodies (PE, APC, FITC) for multi-color analysis

     • Target extracellular epitopes (e.g., AA 1-444 or AA 36-210 )

     • Consider clone MEM-CD148-05 which recognizes an extracellular epitope

  2. Cell preparation protocol:

     • Use enzymatic dissociation methods that preserve surface epitopes

     • Maintain cells at 4°C during processing to prevent receptor internalization

     • For fixed cells, use mild fixatives (0.5-2% paraformaldehyde)

  3. Staining optimization:

     • Titrate antibody to determine optimal concentration

     • Include appropriate isotype controls (e.g., IgG2b for MEM-CD148-05 )

     • Use viability dye to exclude dead cells

  4. Analysis strategies:

     • Gate on specific cell populations of interest

     • Quantify as mean fluorescence intensity (MFI)

     • Determine percentage of positive cells using appropriate thresholds

  5. Cell sorting applications:

     • PTPRJ antibodies can be used for enriching cells expressing the protein

     • Example: APC-coupled anti-PTPRJ antibody was used to purify transduced cells by flow cytometric cell sorting

  Methodological note: After cell sorting, validate comparable PTPRJ expression levels using immunoblotting to ensure experimental groups have equivalent protein expression .

• What approaches can be used to study post-translational modifications of PTPRJ?

  Multiple techniques can reveal PTPRJ modifications:

  1. Glycosylation analysis:

     • Treat immunoprecipitated PTPRJ with glycosidases (PNGase F, Endo H)

     • Compare molecular weight shifts by Western blot

     • Use lectins in combination with PTPRJ antibodies for glycan profiling

  2. Phosphorylation studies:

     • Immunoprecipitate PTPRJ using specific antibodies

     • Probe with anti-phosphotyrosine, anti-phosphoserine, or anti-phosphothreonine antibodies

     • Perform mass spectrometry to identify specific modified residues

  3. Oxidation assessment:

     • Use modified cysteine-reactive probes to detect oxidized catalytic cysteine

     • Compare activity before and after treatment with reducing agents

     • Examine effects of ROS inhibitors (e.g., diphenyleneiodonium/DPI) on PTPRJ activity

  4. Ubiquitination and degradation:

     • Immunoprecipitate PTPRJ and probe for ubiquitin

     • Use proteasome inhibitors to assess degradation pathways

     • Monitor PTPRJ half-life through pulse-chase experiments

  Research insight: PTPRJ activity can be regulated by oxidation. Studies have shown that treating FLT3 ITD-expressing cell lines with the NAD(P)H oxidase inhibitor DPI affects PTPRJ activity and downstream signaling .

• What methodologies can researchers use to investigate PTPRJ's role in contact inhibition and cell density-dependent growth?

  Experimental approaches include:

  1. Density-dependent expression analysis:

     • Culture cells at different densities (sparse to confluent)

     • Quantify PTPRJ levels by Western blot and flow cytometry

     • Perform immunofluorescence to visualize localization changes

  2. Functional studies:

     • Use PTPRJ antibodies to confirm expression in wild-type vs. knockout/knockdown models

     • Assess:

       • Cell proliferation at different densities

       • Contact inhibition markers

       • Downstream signaling pathways

  3. Advanced imaging techniques:

     • Perform live cell imaging with fluorescently-tagged PTPRJ

     • Use TIRF microscopy to examine membrane dynamics

     • Apply super-resolution microscopy to study nanoscale organization

  4. Biochemical assays:

     • Fractionate cells to examine PTPRJ localization to cell-cell junctions

     • Analyze phosphatase activity in sparse vs. confluent cultures

     • Identify density-dependent interaction partners

  Research context: PTPRJ expression increases with increasing cell density, suggesting a role in contact inhibition of cell growth, which is why it's also known as Density Enhanced Phosphatase-1 (DEP-1) .